Dalteparin + Warfarin
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Embolism and Thrombosis
Conditions
Embolism and Thrombosis
Trial Timeline
Sep 1, 2002 → Mar 1, 2006
NCT ID
NCT00216866About Dalteparin + Warfarin
Dalteparin + Warfarin is a phase 2 stage product being developed by Pfizer for Embolism and Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00216866. Target conditions include Embolism and Thrombosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00216866 | Phase 2 | Completed |
Competing Products
20 competing products in Embolism and Thrombosis